Register for our free email digests:
Ian Haydock
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Japan 2010s In Review: Specialize, Focus, Innovate
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Japan Pharma Unconcerned About Virus Impact - For Now
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.
Takeda Ups Guidance On Mainstay Growth, Cost Discipline
Recovering underlying revenue, faster integration synergies and global portfolio growth behind upward adjustments in full-year forecasts.
Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter
Asia Deal Watch: China’s BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics